Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Benjamin Gold

Pediatric Gastroenterology Atlanta, GA Medical Doctor

NPI 1144261868 CMS profile 6968

993-D Johnson Ferry Road, Suite 440, Atlanta, GA 30342

Open in the dashboard

General payments

$78,651

126 records reported · program years 2019–2025

Research payments

$4,847

Paid to them · 8 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$552,594 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Benjamin Gold of Atlanta, GA is reported in the CMS Open Payments database as having received $78,651 across 126 general payments and $4,847 in research payments paid to them. Separately, studies naming them as principal investigator received $552,594 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Pediatric Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $20,368 34
2025 Research $4,431 7
2024 General $6,856 23
2024 Research $417 1
2023 General $11,950 21
2022 General $3,048 13
2021 General $7,783 9
2020 General $2,576 3
2019 General $26,069 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benjamin Gold
  • Pediatric Gastroenterology median
  • Middle half of Pediatric Gastroenterology
  • National median

In program year 2025, general payments to Benjamin Gold were reported at $20,368. Among 1,132 Pediatric Gastroenterology profiles paid that year, the median was $194 and the middle half received between $81 and $540.

Show as a table
Year Benjamin Gold Pediatric Gastroenterology median Middle half National median
2019 $26,069 $131 $41–$311 $163
2020 $2,576 $79 $23–$223 $114
2021 $7,783 $104 $32–$321 $132
2022 $3,048 $125 $37–$331 $149
2023 $11,950 $169 $55–$440 $160
2024 $6,856 $196 $73–$563 $164
2025 $20,368 $194 $81–$540 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $18,000 3 payments
  2. DiaSorin Inc. $16,614 6 payments
  3. DiaSorin S.p.A. $13,955 3 payments
  4. Janssen Scientific Affairs, LLC $12,510 14 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $6,128 12 payments
  6. Regeneron Healthcare Solutions, Inc. $2,965 6 payments
  7. Cipla USA Inc. $2,500 1 payment
  8. Regeneron Pharmaceuticals, Inc. $2,312 2 payments
  9. Genzyme Corporation $1,439 19 payments
  10. QOL Medical, LLC $480 9 payments
  11. Other $1,748 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $48,738 13 payments
  2. Travel and Lodging $10,824 6 payments
  3. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $5,000 1 payment
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,000 1 payment
  5. Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program $5,000 1 payment
  6. Food and Beverage $4,087 102 payments
  7. Education $2 2 payments
Products named General payments · program years 2019–2025
  1. PROTONIX $18,000 3 payments
  2. REMICADE $12,400 13 payments
  3. DUPIXENT Inflammation And Immunology $5,237 7 payments
  4. LANSOPRAZOLE ESOMEPRAZOLE $2,500 1 payment
  5. DUPIXENT Immunology $1,314 17 payments
  6. Sucraid Therapy For Csid $237 2 payments
  7. Sucraid Therapy For Csid $213 6 payments
  8. HUMIRA $153 9 payments
  9. EndoFlip $149 2 payments
  10. TZIELD $124 1 payment
  11. Other $1,054 49 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $4,847 8 payments

Records

134 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Gastroenterology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record